Follicular Lymphoma
The latest news, research, and perspectives in follicular lymphoma (FL).
The MZL cohort of a phase 2 study saw the most success from the atezolizumab plus obinutuzumab and venetoclax regimen.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
The name change will take effect on August 28, ahead of Blood Cancer Awareness Month in September.
In the RELATIVITY-022 study, the combination's efficacy was greatest in Hodgkin lymphomas naive to PD-1 or PD-L1 inhibition.
The study investigated the role of multi-cancer early detection tests (MCEDs) on patient survival outcomes.
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
FDA approves tafasitamab plus R2 for relapsed FL, showing 57% reduced risk of progression in phase 3 inMIND trial.
The approval of tafasitamab-cxix in combination with rituximab and lenalidomide was based on the phase 3 inMIND trial.
Mosunetuzumab’s mechanism of action involves connecting B-cells with T-cells for elimination by the immune system.
Peripheral blood samples were analyzed within a phase 2 trial of this bispecific antibody as 1L treatment for FL and MZL.
Of 128 efficacy-evaluable patients, the ORR was 80.5% and the CR rate was 74.2% at a median follow-up of 28.3 months.
A phase 2/3 trial is evaluating zilovertamab vedotin plus rituximab and gemcitabine-oxaliplatin in relapsed/refractory DLBCL.
Steady access to Medicaid insurance helps ensure early recognition of symptoms, said senior author Xu Ji, PhD.
The global phase 3 RCT is part of an sBLA for glofitamab plus gemcitabine and oxaliplatin use in R/R DLBCL NOS.
Axi-cel shows durable response in high-risk LBCL frontline treatment with 80% progression-free at 3 years in ZUMA-12 trial.
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
Efficacy and safety profile data were presented at the AACR Annual Meeting 2025.
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
The Community Oncology Alliance outlined solutions for Congress to address systemic challenges of the U.S. healthcare system.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.